Literature DB >> 10933133

In-vitro in-vivo correlation models for glibenclamide after administration of metformin/glibenclamide tablets to healthy human volunteers.

G Balan1, P Timmins, D S Greene, P H Marathe.   

Abstract

In this study, level C and A in-vitro in-vivo correlation (IVIVC) models were developed for glibenclamide. In-vitro dissolution data were collected for the glibenclamide component of three metformin/glibenclamide tablets using a USP Type II apparatus. In-vivo plasma concentration data were obtained after administration of the prototype formulations to 24 healthy volunteers and subject to deconvolution analysis to obtain percentage in-vivo absorbed profiles. Multiple linear level C models were developed for CMAX and AUC(0-48) using percentage in-vitro dissolved data at 10, 45 and 120 min. Initially, the level A model was constructed for the first 2 h only, based on availability of in-vitro data. Another level A model was attempted using a time-scaled approach, with percentage in-vivo absorbed at time t and percentage in-vitro dissolved at time t/I as the correlating data. Internal predictability was evaluated for the level C and time-scaled level A models. For all level C approaches, linear regression models with r2 > 0.99 were determined. The prediction errors (% PE) for Cmax and AUC(0-48) were less than 1% for all formulations at all three chosen time points. The deconvolution analysis indicated biphasic absorption for glibenclamide, with one phase occurring at 2-3h and another at 6-12h after dose administration. The level A model using 2-h data was not unique for all formulations and was therefore not developed. The time-scaling factor I correlated highly (r2 = 0.99) with in vitro mean dissolution time (MDT). A linear regression time scaled model (r2 = 0.97) was successfully developed using in-vitro and in-vivo data from all 3 formulations. However, the internal predictability of the time-scaled model was poor, with % PE values for Cmax and AUC(0-48) being as much as 30.5% and 18.7%, respectively. The results indicate that level C models have good internal predictability. Though a time-scaled level A IVIVC model was successfully developed, the model was found to have poor internal predictability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933133     DOI: 10.1211/0022357001774688

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

Review 1.  Synergic development of pharmacokinetics and bioanalytical methods as support of pharmaceutical research.

Authors:  M Marzo; R Ciccarelli; P Di Iorio; P Giuliani; F Caciagli; A Marzo
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

2.  Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations.

Authors:  Elena Soto; Sebastian Haertter; Michael Koenen-Bergmann; Alexander Staab; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2009-12-29       Impact factor: 4.200

3.  Development, Internal and External Validation of Naproxen Sodium Sustained Release Formulation: an Level A In Vitro-In Vivo Correlation.

Authors:  Ramesh Narayanasamy; Ramakrishna Shabaraya
Journal:  Turk J Pharm Sci       Date:  2017-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.